- US-listed companies
- CAPRICOR THERAPEUTICS, INC.
- Income statement
CAPRICOR THERAPEUTICS, INC.CAPR
Market cap
$1.2B
P/E ratio
| 2011/12 | 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | 2 | 2 | - | 5 | 6 | 4 | 3 | 2 | 1 | 310,250 | 244,898 | 3 | 25 | 22 |
| Revenue growth (%) | - | - | - | |||||||||||
| Research & development | 30 | 31 | 11 | 8 | 14 | 16 | 11 | 12 | 5 | 8 | 14 | 22 | 36 | 50 |
| Operating margin (%) | - | |||||||||||||
| Operating income | -4,899,180 | -2,440,140 | -6,902,900 | -6,017,985 | -12,611,826 | -16,976,518 | -12,862,397 | -15,327,086 | -7,733,888 | -13,689,971 | -20,938,442 | -29,697,383 | -24,077,859 | -42,564,842 |
| Operating expenses | 46 | 49 | 18 | 11 | 18 | 21 | 16 | 17 | 9 | 14 | 21 | 32 | 49 | 65 |
| Net income | -4,884,786 | -46,708,017 | -8,891,924 | -6,216,592 | -12,857,339 | -18,806,776 | 2 | -15,191,095 | -7,641,817 | -13,657,028 | -20,022,520 | -29,019,532 | -22,287,542 | -40,467,186 |
| Net income margin (%) | - | |||||||||||||
| Earnings per share | - | - | - | - | - | - | 0.1 | - | - | - | -0.87 | -1.18 | -0.83 | -1.15 |
| Diluted EPS | - | - | - | - | - | - | 0.09 | -0.52 | - | - | -0.87 | -1.18 | -0.83 | -1.15 |
| EBITDA | ||||||||||||||
| EBITDA margin (%) | - |